Ipsen’s mission, “innovation for patient care”, highlights our determination to focus on patients and unmet medical needs and to provide innovative therapeutic solutions. Our ambition for R&D is based on an intensified partnership policy, a promising pipeline, one technological platform specializing in toxins, and three benchmark R&D centres around the world.
One innovative scientific platform
Ipsen has a leading-edge technological platform in toxins, in which we stand out for our acknowledged expertise. This specialist knowledge also opens the door to the possibility of strong external partnerships in the field. With their unique properties, toxin molecules offer potential in the treatment of neuromuscular disorders, as well as for pain and aesthetic medicine.
3 R&D centres
Ipsen has set-up its R&D centres at the heart of three internationally reputed scientific hubs: Paris-Saclay in France, Oxford in the United Kingdom, and Cambridge in the United States. Each site is located close to leading academic research centres, cutting-edge medical centres and biotechnological companies.
Ipsen’s Research & Development comprises both new molecule development programs and lifecycle management programs for our existing products. During preclinical and clinical development, early identification of therapeutic targets and markers helps researchers to better define the potential value of molecules. This speeds up the process of drug development and drug approval application procedures.
Ipsen’s active partnership policy underpins internal R&D, from fundamental research through to clinical development.